Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy for Patients with Genotype 2 Chronic Hepatitis C Infection Who Failed HCV Eradication by SOF+RBV Treatment

DOI Web Site Web Site 1 Citations 3 References
  • Watanabe Shunji
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Miura Kouichi
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Morimoto Naoki
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Murohisa Toshimitsu
    Department of Gastroenterology, Dokkyo Medical University
  • Tano Shigeo
    Department of Gastroenterology, Shin-Oyama City Hospital
  • Tahara Toshiyuki
    Department of Gastroenterology, Saiseikai Utsunomiya Hospital
  • Okamura Yukishige
    Department of Gastroenterology, Sano Kousei General Hospital
  • Fukaya Yukimura
    Department of Internal Medicine, Nasu Minami Hospital
  • Sato Takashi
    Department of Gastroenterology, Nasu Red Cross Hospital
  • Iijima Makoto
    Department of Gastroenterology, Yuai Memorial Hospital
  • Numao Norikatsu
    Department of Gastroenterology, Haga Red Cross Hospital
  • Hirosawa Takuya
    Department of Gastroenterology, Haga Red Cross Hospital
  • Kurata Hidekazu
    Department of Gastroenterology, Tochigi Medical Center Shimotsuga
  • Murayama Kozue
    Department of Gastroenterology, Koga Red Cross Hospital
  • Uehara Keita
    Department of Gastroenterology, National Hospital Organization Tochigi Medical Center
  • Yoshizumi Hiroaki
    Department of Internal Medicine, Kamitsuga General Hospital
  • Nakazawa Katsuyuki
    Department of Gastroenterology, Japan Community Health Care Organization Utsunomiya Hospital
  • Sugaya Hitoshi
    Department of Internal Medicine, Utsunomiya Higashi Hospital Department of Gastroenterology, Ashikaga Red Cross Hospital
  • Goka Rie
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Nomoto Hiroaki
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Takaoka Yoshinari
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Tsukui Mamiko
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Isoda Norio
    Department of Medicine, Division of Gastroenterology, Jichi Medical University
  • Yamamoto Hironori
    Department of Medicine, Division of Gastroenterology, Jichi Medical University

Bibliographic Information

Other Title
  • グレカプレビル/ピブレンタスビル治療はゲノタイプ2型C型慢性肝疾患に対するソフォスブビル＋リバビリン治療のウイルス学的無効例に有効である
  • グレカプレビル/ピブレンタスビル チリョウ ワ ゲノタイプ 2ガタ Cガタ マンセイ カン シッカン ニ タイスル ソフォスブビル+リバビリン チリョウ ノ ウイルスガクテキ ムコウレイ ニ ユウコウ デ アル

Search this article

Abstract

<p>Although sofosbuvir plus ribavirin (SOF+RBV) treatment is highly effective for genotype 2 chronic hepatitis C infection, 3%-7% of patients failed to achieve a sustained virologic response (SVR). As the optimal combination of direct-acting antivirals remains unclear, we conducted a multicenter trial using 12-week Glecaprevir/Pibrentasvir (GLE/PIB) therapy for patients who failed to achieve an SVR by SOF+RBV treatment. We encountered 13 patients; 9 men and 4 women. Of 13 patients, 10 were genotype 2a and 3 were genotype 2b. The rates of rapid virologic response, expected treatment response, and SVR12 were 92.3%, 100%, and 100%, respectively. Adverse events were observed in 4 cases (30.8%), which were mild events. In conclusion, 12-week GLE/PIB therapy is highly effective for patients who did not achieve SVR by SOF+RBV treatment.</p>

Journal

  • Kanzo

    Kanzo 60 (2), 77-79, 2019-02-20

    The Japan Society of Hepatology

Citations (1)*help

See more

References(3)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top